去纤苷中国上市了吗？

(Alias: defibrotide sodium) is a drug containing the active substance defibrotide. It is used to treat severe veno-occlusive disease (VOD) in patients undergoing hematopoietic (blood) stem cell transplantation. Defibrotide is used for adults and one-month-old children. Is defibrotide available on the market in China?

It is understood that defibrotide has not been officially launched in China yet, and patients can purchase the version launched abroad!

Defibrotide (alias: defibrotide sodium), which is marketed abroad, has a specification of 200mg and a price of around 20,000$. Due to the floating exchange rate, the price is different. Please consult the medical companion for the specific price!

Hepatic veno-occlusive disease (VOD), also known as sinus obstruction syndrome (SOS), is a fatal form of liver injury and chronic complication associated with HSCT. Within 21 days after HSCT, the sinusoidal endothelial cells of the liver were affected. Liver VOD occurs in 9%-14% of HSCT patients and is life-threatening in 30-50% of cases. VOD conditions are also associated with kidney conditions or lung dysfunction, often referred to as multiple organ dysfunction (MOD), which can lead to mortality rates as high as 84% ​​in patients.

The disease is often characterized by symptoms such as weight gain, hepatomegaly (enlargement of the liver), and elevated bilirubin. Chronic hepatic VOD is also associated with fatigue and abdominal distension as well as symptoms of portal hypertension, edema, ascites, varicose veins, hepatic encephalopathy or muscle wasting and weakness.

Due to the small number of people with VOD, the disease is considered "rare," and on July 29, 2004, (alias: defibrotide sodium) was designated an "orphan drug" (a drug used for rare diseases).

Recommended related hot articles: /newsDetail/81089.html